NEWS

Our latest news and press releases.

2023

2022

2021

December 2

2020

2021-05-17T18:52:30+01:00

Cycle Announces the Appointment of Angela Kurtz as Clinical Metabolic Director to lead its newly created Clinical Metabolic Department

October 19

2020

2021-05-17T18:52:30+01:00

Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in Israel

September 14

2020

2021-05-17T18:52:30+01:00

US FDA Grants Once Daily Dosing Option For NITYR (nitisinone) Tablets for HT-1 Patients

September 8

2020

2022-12-21T13:19:26+00:00

Dr David Buckeridge Joins Cycle Group Holdings’ Board of Directors

September 8

2020

2022-12-21T13:17:11+00:00

Cycle Pharmaceuticals Features in the Sunday Times Tech Track Ones to Watch 2020

September 5

2020

2022-12-21T13:10:50+00:00

Cycle Pharmaceuticals Secures $25 Million Debt Financing

August 5

2020

2022-12-21T13:09:20+00:00

Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1)

May 13

2020

2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in the Kingdom of Saudi Arabia

May 5

2020

2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology

April 19

2020

2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals Launches New Informative Online Meeting Series for Patients With Tyrosinemia Type 1 in the US

March 13

2020

2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals’ Supply Chain update

December 18

2019

2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics

October 31

2019

2022-01-28T15:52:20+00:00

Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases using Zydis ODT Technology

April 28

2019

2021-05-17T18:52:31+01:00

NITYR (nitisinone) Tablets for tyrosinaemia type 1 will be available with fully subsidised access on the Life Saving Drugs Program across Australia

November 22

2018

2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile

November 19

2018

2021-05-17T18:52:31+01:00

Longer shelf life for NITYR (nitisinone) tablets for HT-1 in the U.S. granted by the FDA

November 12

2018

2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals Receives Approval for Updated Infant Administration for NITYR (nitisinone) Tablets for HT-1 in U.S.

August 29

2018

2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals Receives FDA Approval and Launches Ketorolac Tromethamine Injection 30mg/mL in the U.S.

August 29

2018

2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals Receives FDA Approval for Ketorolac Tromethamine Tablets in the U.S.

November 10

2017

2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals launches free trial of NITYR in the US and Partners with Cambrooke Therapeutics to Support HT-1 Patients’ dietary needs

August 1

2017

2021-05-17T18:52:31+01:00

Cycle Pharmaceuticals Receives FDA Approval of Nityr™ (nitisinone) Tablets for Treatment of HT-1

June 2

2017

2022-10-12T15:48:30+01:00

First recommendation for HT-1 treatment in Quebec by INESSS

December 19

2016

2021-05-17T18:52:31+01:00

CYCLE Pharmaceuticals, The University of Cambridge and King’s College London Partner to Repurpose PARP Inhibitor Drugs for Vascular Disease

November 8

2016

2021-05-17T18:52:31+01:00

CYCLE Pharmaceuticals Nitisinone Tablets Approved by Health Canada for the Treatment of HT-1

FOLLOW US
ABOUT US
TECHNOLOGY PARTNERSHIPS